Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
Crystalys Therapeutics has raised $205.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Crystalys Therapeutics's investors include SR One, Novo Holdings, Longwood Fund, Alexandria Venture Investments, Lightstone Ventures.
Crystalys Therapeutics is headquartered in San Diego, United States.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
Crystalys Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Crystalys Therapeutics — Funding & Investors." VCBacked, September 30, 2025, https://www.vcbacked.co/company/crystalys-therapeutics. Accessed July 23, 2026.
VCBacked. (2025). Crystalys Therapeutics — Funding & Investors. Retrieved July 23, 2026, from https://www.vcbacked.co/company/crystalys-therapeutics
{{cite web |title=Crystalys Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/crystalys-therapeutics |website=VCBacked |access-date=July 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated